



1600

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Douglas J. Jolly et al.

11033

11033
11/2/98

Serial No.: 09/001,039

Group Art Unit: to be assigned

Filed : December 30, 1997

Examiner: to be assigned

For : METHODS FOR ADMINISTRATION OF RECOMBINANT
GENE DELIVERY VEHICLES FOR TREATMENT OF
HEMOPHILIA AND OTHER DISORDERS

5

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56 AND §1.97(b)(3)

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The citations listed on the enclosed Supplemental Information Disclosure Form PTO-1449 may be material to the examination of the above-identified patent application. Therefore, Applicants submit these documents in compliance with the duty of disclosure as defined in 37 C.F.R. §1.56 and §1.97(b)(3). The Examiner is requested to make these citations of official record in the present application.

Also enclosed herewith are copies of International Search Report for PCT International Application Nos. PCT/US97/11784 and PCT/US97/11785.

The present Supplemental Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore, no certification under 37 C.F.R. §1.97(e) or fee under 37 C.F.R. §1.17(p) is required.

This Supplemental Information Disclosure Statement under 37 C.F.R. §1.56 and §1.97(b)(3) is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these citations constitute prior art under 35 U.S.C. §102 or §103.

*I hereby certify that this correspondence is
being deposited with the United States
Postal Service as first class mail in an
envelope addressed to: Box _____
Commissioner of Patents and Trademarks,
Washington, D.C. 20231, on this*
day of March, 19 98
By [Signature]

The Commissioner is hereby authorized to charge any fees in connection with this Supplemental Information Disclosure Statement to Deposit Account No. 03-1664. This, however, is not an authorization for payment of issue fee.

Respectfully submitted,

By:



Paul B. Saveride, Ph.D.
Attorney for Applicants
Reg. No. 36,914

March 06, 1998

CHIRON CORPORATION
Intellectual Property - R440
P.O. Box 8097
Emeryville, California 94662-8097
(510) 923-2585
(510) 655-3542 (fax)